Replies to post #84671 on CV Sciences Inc (CVSI)

[Wolf-man jack]

WQLF SAYS: Once again YQU keep posting mis-information in reference to CV SCIENCES not in - sourcing YQU will Understand YQU Understand. That is Why they are saving the 34 million reserved Evergreen Plan shares for. Further acquisitions...HAVE MERCY WQLF ahoooooo

Ai Generated

Yes, CV Sciences acquired Elevated Softgels in May 2024 to in-source the manufacturing of its +PlusCBD™ products.
Key details regarding the acquisition include:

Purpose: The acquisition was designed to bring manufacturing in-house to achieve cost efficiencies, improve gross margins, and increase flexibility in production.

Transaction: The deal, completed on May 13, 2024, included a $100,000 cash payment and 17,422,181 shares of CV Sciences common stock, with a potential additional earn-out of up to $200,000.

Operations: Elevated Softgels, a Colorado-based, profitable, low-MOQ (minimum order quantity) manufacturer, operates as a wholly-owned subsidiary of CV Sciences.

Impact: The integration is expected to improve financial performance, with the company projecting improved cost efficiency and gross margins in the second half of 2025.

During 2023, softgels and tinctures comprised approximately 50% of CV Sciences' total business, making the in-sourcing of these products a key strategic move

Ai Generated:

Yes, CV Sciences has traditionally used a model that relies on contract manufacturers for the production of their +PlusCBD™ products, but they also use a qualified, controlled supply chain and are increasingly moving toward in-sourcing production.

Key details regarding their production model:

Supplier Qualification Program: CV Sciences utilizes a rigorous supplier qualification program, which includes reviewing the quality systems and processes of their contract manufacturers.

Quality Control: While they outsource manufacturing, they maintain control by having each lot of blended hemp extract tested for identity, purity, and strength by independent ISO-17025 laboratories.

Manufacturing Partners: Their products are produced under cGMP conditions by qualified contract manufacturers.
In-Sourcing Strategy: In late 2024, CV Sciences entered into an agreement to acquire Extract Labs, a GMP-certified and FDA-registered manufacturer. A primary goal of this acquisition is to "in-source the manufacturing of select +PlusCBD™ branded products" allowing them to move away from relying solely on external manufacturers.

Domestic Sourcing: The company has a strong focus on a domestic supply chain for their (raw materials), with, for instance, a 2019 initiative focusing on 500+ acres of U.S.-based hemp production.

In summary, while historically relying on outsourced manufacturing, CV Sciences is transitioning to in-house production for key products through acquisitions. ...

[Wolf-man jack]

WQLF SAYS : WRONG AGAIN STORY TELLER. HAVE MERCY WQLF ahoooooo

Dr. Joong J Fang Said:: The reason Joseph Dowling did not increase the 4 percent increase of Shares towards the 34 Million Shares in the Evergreen Plan is because the 33,333,333 MILLION Shares were no longer needed because the Extract Labs Acquisition did not get approved by the Seller. Now You know the reason you will kick yourself in the Anus when all the planets align.

Taleteller Said:

They outsource all their CBD manufacturing, right?

Ai Generated:

CV Sciences, Inc. acquired Elevated Softgels, LLC in May 2024 with the explicit goal of investing in new equipment and personnel to increase capacity, specifically to support the expansion of their product lines, including gummies and softgels.


Key details regarding this expansion include:

Acquisition and Investment: CV Sciences closed the acquisition of the Colorado-based manufacturer on May 13, 2024, to bolster their manufacturing capabilities.

Capacity Increase: The company is investing in new equipment and staffing to increase the capacity of the Elevated Softgels facility, aiming to produce a higher volume of products.

Focus on Product Lines: The focus includes leveraging the facility for gummies and, as the name suggests, softgels, in addition to other nutraceutical products.

In-sourcing Strategy: A primary motivation for the acquisition is to in-source the production of CV Sciences’ existing products, such as their +PlusCBD™ lines, to improve margins and control quality.

Operational Flexibility: Elevated Softgels, now a wholly-owned subsidiary, provides flexibility for both low and large-volume production runs.

As of late 2025, CV Sciences continues to invest in the Elevated Softgels facility to support the launch of new products and increase market share.

Wolf Said : Have Mercy ahoooooo